Diabetes

Tirzepatide is a once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist indicated as an adjunct to diet and exercise in adults with type 2 diabetes.

Investigators analyzed data from nearly 4000 individuals from the National Longitudinal Study of Adolescent to Adult Health.

Individuals with type 2 diabetes who use insulin are often restricted when accessing continuous glucose monitoring systems.

Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.

Investigators develop a genetic-risk score to identify those who would benefit most from lifestyle counseling to prevent the condition.

Spending 1 hour less sitting a day and increasing light physical activity helps prevent diseases, investigators find.

Pharmacists are well suited to help patients overcome the barriers that prevent access to therapy regimens.

Investigators find that 1 45-minute session of moderate intensity exercise allows more exosomes to deliver the protein, ATP7A, directly to endothelial cells, which can help enable angiogenesis.

Clinical trial participants who took the drug lost up to 52 lb., or 24 kg, in the 72-week, phase 3 study.

Ertugliflozin (Steglatro) is a sodium glucose co-transporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

The company’s analysis shows data for the automated insulin delivery system for both T1D and T2D.

Thiazolidinediones may change metabolic patterns and contribute to weight gain.

Individuals with diabetes, a higher body mass index, or a history of hospitalization are more likely to develop the condition, the analysis shows.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discusses what biosimilars in the pipeline are expected to launch this year.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Here are 8 diabetes areas where pharmacists should be more aware of error.

It is imperative for health care professionals, especially pharmacists, to be well-informed regarding the physiological impact of Ramadan on diabetes.

With the FDA approval and launch of the first interchangeable biosimilar in the United States in 2021, retail pharmacists are poised to play an increasing role in the future uptake of biosimilars.

Pharmacy Quality Alliance's new benchmark evaluates adherence to medications for diabetes, high cholesterol, and hypertension.

In a clinical trial, 86.4% of patients on semaglutide achieved a 5% weight loss at week 68 compared to 31.5% with placebo.

On average, patients visit their community pharmacist 12 times more often than they do their primary care provider

How would you handle these patients' questions?

Semaglutide (Ozempic; Novo Nordisk) approved as a once-weekly subcutaneous injection for the treatment of adults with type 2 diabetes.

Omnipod 5 allows patients with diabetes to receive 72 hours of continuous, automated insulin administration.